Posted by Michael Wonder on 01 Aug 2018
FDA supports critical research to spur innovation for continuous manufacturing technology to support and advance drug and biologics development
1 August 2018 - We know that novel manufacturing technologies for both small-molecule drugs and biological products have great potential to accelerate the development of new therapies and reduce the cost of critical medicines.
Continuous manufacturing utilises technologies that offer clear benefits for both patients and industry. The approach has the potential to shorten production times and improve the efficiency of manufacturing processes.
These benefits translate to lower cost of production and thus the cost of medicine. It also allows for more nimble monitoring and control that can help reduce the likelihood of manufacturing failures, which in turn can reduce the risk of drug shortages.
